Renal safety of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis: results from HORIZON-PFT

被引：0
|
作者：
Miller, P.
Sellmeyer, D.
Boonen, S.
机构：
来源：
OSTEOPOROSIS INTERNATIONAL | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S129 / S130
页数：2
相关论文
共 50 条
  • [41] Effect of previous bisphosphonate use on response to zoledronic acid: Results from the HORIZON-PFT study
    Lippuner, Kurt
    Eastel, Richard
    Reid, Fan
    Benhamou, Claude-Laurent
    Recknor, Chris
    Ish-Shalom, Sophia
    Bianchi, Gerolaino
    Black, Dennis
    Mesenbrink, Peter
    Eriksen, Erik Fink
    Delmas, Pierre D.
    BONE, 2008, 42 : S77 - S77
  • [42] EFFICACY AND SAFETY OF ZOLEDRONIC ACID 5 MG IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA: THE HORIZON PREVENTION STUDY
    McClung, Michael R.
    Miller, Paul
    Recknor, Christopher
    Ruzucky, Maryellen
    BucciRechtweg, Christina
    Yu, Sue
    Benhamou, Claude Laurent
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S212 - S213
  • [43] Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT
    Sambrook, Philip N.
    Silverman, Stuart L.
    Cauley, Jane A.
    Recknor, Chris
    Olson, Melvin
    Su, Guoqin
    Boonen, Steven
    Black, Dennis
    Adachi, Jonathan D.
    BONE, 2011, 48 (06) : 1298 - 1304
  • [44] The effects of zoledronic acid 5 mg once-yearly on bone remodeling and structure in osteoporotic women are consistent across age
    Recker, R. R.
    Delmas, P.
    Reid, I.
    Boonen, S.
    Halse, J.
    Garcia, P.
    Supronik, J.
    Lewiecki, M.
    Ochoa, L.
    Miller, P.
    Hartl, F.
    Gasse, J. A.
    Mesenbrink, P.
    Hu, H.
    Eriksen, E.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S129 - S129
  • [45] DOES ZOLEDRONIC ACID INCREASE RISK OF ATYPICAL FEMORAL SHAFT FRACTURES? RESULTS FROM THE HORIZON-PFT
    Genant, H. K.
    Bucci-Rechtweg, C.
    Bauer, D. C.
    Mesenbrink, P. G.
    Palermo, L.
    Nusgarten, L.
    Eastell, R.
    Black, D. M.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 161 - 162
  • [46] Effect of once-yearly zoledronic acid 5 mg on 'Super Six' non-vertebral fractures
    Black, D. M.
    Eastell, R.
    Cosman, F.
    Man, Z.
    Bucci-Rechtweg, C.
    Mesenbrink, P.
    BONE, 2009, 44 (02) : S429 - S429
  • [47] Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project
    Carbonare, L. Dalle
    Bertoldo, F.
    Lo Cascio, V.
    REUMATISMO, 2009, 61 (01) : 54 - 64
  • [48] EFFECT OF ONCE-YEARLY ZOLEDRONIC ACID IN MEN AFTER RECENT HIP FRACTURE: RESULTS FROM HORIZON RECURRENT FRACTURE TRIAL
    Boonen, Steven
    Kaufmann, Jean-Marc
    Orwoll, Eric
    Magaziner, Jay
    Colon-Emeric, Cathleen
    Adachi, Rick
    Bucci-Rechtweg, Christina
    Haentjhens, Patrick
    Vanderschueren, Dirk
    Lyles, Kenneth
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 180 - 180
  • [49] Bone Material Properties in Actively Bone-Forming Trabeculae in Postmenopausal Women With Osteoporosis After Three Years of Treatment With Once-Yearly Zoledronic Acid
    Gamsjaeger, Sonja
    Buchinger, Birgit
    Zwettler, Elizabeth
    Recker, Robert
    Black, Dennis
    Gasser, Juerg A.
    Eriksen, Erik F.
    Klaushofer, Klaus
    Paschalis, Eleftherios P.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (01) : 12 - 18
  • [50] EFFECT OF ONCE-YEARLY IV ZOLEDRONIC ACID IN MEN AFTER HIP FRACTURE: RESULTS FROM THE HORIZON-RECURRENT FRACTURE TRIAL
    Boonen, S.
    Magaziner, J.
    Lyles, K.
    Colon-Emeric, C.
    Adachi, J.
    Bucci-Rechtweg, C.
    Mesenbrink, P.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 84 - 84
12345